平衡与不平衡晶体液作为心源性休克复苏液的比较
该回顾性分析纳入慕尼黑大学医院2010至2022年1032例倾向性评分匹配的心源性休克患者,2018年起默认复苏液由0.9%生理盐水改为平衡晶体液。生理盐水组(n=516)与平衡晶体液组(n=516)30天死亡率相似(43.1% vs 43.0%,p=0.833),但生理盐水组新发肾脏替代治疗率更高(30.2% vs 22.7%,p=0.007)且儿茶酚胺剂量显著更高。在院外心脏骤停后乳酸>7.4 mmol/L的亚组中,生理盐水组30天死亡率显著低于平衡晶体液组(58.6% vs 79.3%,p=0.013);院外心脏骤停后多因素Cox回归显示使用平衡晶体液与更高死亡率独立相关(HR 1.43,95%CI 1.05-1.96,p=0.024)。
要点
- 心源性休克患者使用平衡晶体液与生理盐水30天死亡率相似(43.0% vs 43.1%,p=0.833)。
- 生理盐水组新发肾脏替代治疗率高于平衡晶体液组(30.2% vs 22.7%,p=0.007)。
- 生理盐水组儿茶酚胺剂量显著高于平衡晶体液组。
- 院外心脏骤停后乳酸>7.4 mmol/L亚组中,生理盐水组30天死亡率低于平衡晶体液组(58.6% vs 79.3%,p=0.013)。
- 院外心脏骤停后多因素Cox回归显示平衡晶体液与更高死亡率独立相关(HR 1.43,95%CI 1.05-1.96,p=0.024)。
适用人群与场景
- 心源性休克患者,来自慕尼黑大学医院2010至2022年数据,倾向性评分匹配后1032例。
- 包括院外心脏骤停(OHCA)后患者。
处置流程与药物剂量
- 2018年起默认复苏液由0.9%生理盐水改为平衡晶体液。
研究设计与关键结果
- 回顾性分析1032例倾向性评分匹配的心源性休克患者,比较生理盐水(n=516)与平衡晶体液(n=516)复苏。
- 主要终点30天死亡率:生理盐水组43.1% vs 平衡晶体液组43.0%(p=0.833)。
- 新发肾脏替代治疗率:生理盐水组30.2% vs 平衡晶体液组22.7%(p=0.007)。
- 生理盐水组儿茶酚胺剂量显著高于平衡晶体液组。
- OHCA后乳酸>7.4 mmol/L亚组:生理盐水组30天死亡率58.6% vs 平衡晶体液组79.3%(p=0.013)。
- OHCA后多因素Cox回归:平衡晶体液与更高死亡率独立相关(HR 1.43,95%CI 1.05-1.96,p=0.024)。
证据类型、等级与局限
- 证据类型:回顾性分析,倾向性评分匹配。
- 局限:原文未报告局限性。
对床旁实践的改变
- 心源性休克患者使用平衡晶体液与生理盐水30天死亡率相似,但平衡晶体液组新发肾脏替代治疗率更低。
- 在OHCA后严重休克(乳酸>7.4 mmol/L)患者中,使用平衡晶体液与比生理盐水更高的死亡率相关。
指南或共识出处
- LMUshock registry(WHO国际临床试验注册平台编号DRKS00015860)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The efficacy and safety of saline versus balanced crystalloid solutions in ICU-patients remains complicated by exceptionally heterogenous study population in past comparative studies. This study sought to compare saline and balanced crystalloids for fluid resuscitation in patients with cardiogenic shock with or without out-of-hospital cardiac arrest (OHCA).
METHODS: We retrospectively analyzed 1032 propensity score matched patients with cardiogenic shock from the Munich University Hospital from 2010 to 2022. In 2018, default resuscitation fluid was changed from 0.9% saline to balanced crystalloids. The primary endpoint was defined as 30-day mortality rate.
RESULTS: Patients in the saline group (n = 516) had a similar 30-day mortality rate as patients treated with balanced crystalloids (n = 516) (43.1% vs. 43.0%, p = 0.833), but a higher incidence of new onset renal replacement therapy (30.2% vs 22.7%, p = 0.007) and significantly higher doses of catecholamines. However, OHCA-patients with a lactate level higher than 7.4 mmol/L had a significantly lower 30-day mortality rate when treated with saline (58.6% vs. 79.3%, p = 0.013). In addition, use of balanced crystalloids was independently associated with a higher mortality in the multivariate cox regression analysis after OHCA (hazard ratio 1.43, confidence interval: 1.05-1.96, p = 0.024).
CONCLUSIONS: In patients with cardiogenic shock, use of balanced crystalloids was associated with a similar all-cause mortality at 30 days but a lower rate of new onset of renal replacement therapy. In the subgroup of patients after OHCA with severe shock, use of balanced crystalloids was associated with a higher mortality than saline.
TRIAL REGISTRATION: LMUshock registry (WHO International Clinical Trials Registry Platform Number DRKS00015860).
参考来源
- Gmeiner J, Bulach B, Lüsebrink E, et al. Comparison of balanced and unbalanced crystalloids as resuscitation fluid in patients treated for cardiogenic shock. J Intensive Care. 2023. PMID: 37674211. doi:10.1186/s40560-023-00687-y
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。